Investor Profile: Sunstone Capital — Thesis, Cheque Size & How to Apply

For a life science founder in Europe, Sunstone Capital — now Sunstone Life Science Ventures — is one of the most specialised early-stage investors on the continent. Based in Copenhagen, Denmark, the firm was founded in 2007 and backs early-stage life science companies with the potential to succeed globally. If you are building in therapeutics, medical technology or diagnostics, Sunstone funding is worth understanding early, because this is a team that judges a company on its science and its data before anything else.

Thesis and sectors

Sunstone focuses on developing and expanding early-stage life science companies. Its stated hunting ground is pharmaceuticals, medical technologies and diagnostics, and it looks for teams whose innovation can improve patient outcomes at scale. The firm describes itself as an independent European venture capital investor staffed by people with entrepreneurial, operational and financial experience, not just finance backgrounds. Sunstone says it evaluates 10 to 20 opportunities in a single week, so a pitch must be sharp, evidence-led and self-explanatory.

Fund size and track record

Sunstone has managed total funds of €500 million, according to its own company releases, and since inception it has invested in more than 60 companies and completed more than 25 successful IPOs and large M&A transactions.

Notable portfolio companies

Two names illustrate the thesis well. MinervaX, a Copenhagen biotech developing a protein-only vaccine against Group B Streptococcus for maternal immunisation, raised an upsized €47.4 million Series B in which Sunstone was an existing investor. Resalis Therapeutics, an Italian company working on a microRNA-based treatment for obesity, raised a €10 million Series A led by Sunstone to complete a first-in-human Phase I study. Both cases show a willingness to back technically demanding, clinically staged science rather than chasing quick commercial wins.

Team and founder support

The firm’s senior team includes Søren Lemonius, Managing General Partner, Peter Benson, Chairman and General Partner, and General Partners Sten Verland and Claus Andersson. Sunstone also publishes unusually candid fundraising guidance for founders, its 10 Advisements, distilled from more than 5,000 pitch presentations seen over 18 years. Its advice is blunt: prepare meticulously, keep the deck to no more than 30 slides, let the innovation and the data take centre stage, and never let an adviser stand between you and the investor. No separate credits or perks programme is advertised on its public materials; the value on offer is specialist judgement, board-level help and a network built over nearly two decades in European life sciences.

How to apply for funding from Sunstone Capital

There is no public application form to complete, so how to get funding from Sunstone Capital follows the normal venture route: approach the team through its website at sunstone.eu with a concise, data-rich deck, ideally introduced by a trusted founder, clinician or co-investor. Lead with the unmet medical need, the mechanism, the clinical evidence so far and a credible plan and budget to the next value inflection point. Expect detailed diligence on the science, intellectual property and clinical strategy, and be ready to share data generously, since Sunstone says a single compelling figure can be what earns a follow-up meeting.